Platform Availability
AMP North, APEX NZ, BT Asgard, BT Panorama, CFS Edge, Dash, Hub24, IOOF Expand, Centric, Hub24, Macquarie Wrap - IDPS & Super, Mason Stevens - IDPS & Super, Netwealth - IDPS & Super, Praemium - IDPS, Super, SMA & Powerwrap
Description
The Pengana Australian Equities Fund aims to enhance and preserve investor wealth over a 5- year period via a concentrated core portfolio of principally Australian listed securities. The Fund uses fundamental research to evaluate investments capable of generating the target return over the medium term. Essentially, we are in the business of seeking to preserve capital and make money – we are not in the business of trying to beat the market. We remain focused on acquiring and holding investments that offer predictable, sustainable and well-stewarded after-tax cash earnings yields in excess of 6% that will grow to double digit levels as a percentage of our original entry price in five years. We believe that building a well-diversified portfolio of these “gifts that keep on giving” represents a meaningful way to create and preserve financial independence for our co-investors.
COMMENTARY
The strong rebound in the stock market since the lows of March continues to moderate, with the Australian stock market up 0.9% in July. By comparison, The Pengana Australian Equities Fund returned 1.5%.
Over recent months, market sentiment has swung from pure panic in March, bargain hunting and speculation (particular from first-time retail investors) in April and May, to a semblance of normality in June and July.
However, there are many reasons for caution for an equity investor at this juncture. Most pressing is, of course, the re-emergence of COVID-19 in Victoria with the State going into almost complete lock-down. This is clearly negative for the Australian economy as a whole and the risk that such measures spread to other states cannot be ignored. This “second wave” phenomenon also appears to be gathering pace across the globe, with obvious negative implications for global trade.
We are also just about to enter the reporting season for most companies’ fiscal 2020 year results. It promises to be a sobering experience and for investors, it will be the first opportunity to see the damage that the past 6 months have wrought on their investee companies. Whilst many investors understand that FY20 has been unusual, to say the least, and are focusing their attention on the prospects for FY21 and beyond, it is more difficult than ever for companies to give any forward-looking guidance. On balance, we feel that managements will err on the side of caution when making comments on the outlook for their businesses. It is likely that guidance statements for FY21 will be either very wide or deferred to a later date, possibly the annual general meeting season in November.
We also expect to see a fresh round of capital raisings associated with results announcements and that may also exert downward pressure on stocks as funds are diverted towards new issues at discounted prices.
On the political front, things are no rosier with what looks like an ever-worsening relationship between China and the USA. The US presidential election in November looms large and it is hard to see a let-up in the anti-Chinese rhetoric in the lead-in.
Of course, all of the above reasons for caution may be completely overshadowed (in the short term at least) should there be an announcement of an approved vaccine against COVID-19. There have never been so many resources poured into a search for a vaccine and in recent weeks we have heard of several promising preliminary results from credible research organisations.